Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO. Formerly the company's chief finance officer, Hubertus von Baumbach has been in ...

In a question and answer session at the company's annual results conference in Germany today, managing director Hubertus von Baumbach noted that Spiriva's patent had expired in the US. But he said ...

Spiriva capsules contain 18 mcg of tiotropium and are light green, with the Boehringer Ingelheim company logo on the Spiriva capsule cap and TI 01 on the Spiriva capsule body, or vice versa.

Much like Nifty companies, pharma giants are now facing a slowdown in earnings growth. After enjoying a joyride through FY24, posting record revenues quarter after quarter, several pharma companies ...

Tiotropium (as bromide monohydrate) 1.25mcg, 2.5mcg; per actuation; inh spray; contains benzalkonium chloride. Spiriva Respimat Inhalation Spray is supplied in a carton containing one Spiriva ...

Boehringer Ingelheim is also planning to cut the list prices for Spiriva HandiHaler and Atrovent HFA ... medicines including an ongoing commitment to responsible pricing,” a company spokesperson said.

The Indian pharmaceutical sector faces mixed growth with a 12% YoY and 5% QoQ rise while IPM growth is projected at 8%.

Sumit Gupta, AVP Research at Centrum said that Sun Pharma is likely to report good growth, led by its specialty segment with ...

McKinsey & Company has been provided strategic advice to corporations and other organizations since 1926, when James O. McKinsey, a University of Chicago professor, opened a consulting office in ...

Tiffany & Co. is a holding company, which engages in design, manufacture, and sale of jewelry. The firm also sells timepieces, leather goods, sterling silver goods, china, crystal, stationery ...

The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...

But the YoY growth is expected to decline for the Indian Pharmaceutical Market (IPM), projected at approximately 8 per cent, ...